Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Fund” third-quarter 2025 investor ...

Fintel reports that on January 12, 2026, Barclays downgraded their outlook for Insulet (NasdaqGS:PODD) from Equal-Weight to ...

Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced it will report financial ...

Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming quarters. The rising adoption of ...

As of November 17, 2025, the average one-year price target for Insulet is $378.99/share. The forecasts range from a low of $319.16 to a high of $449.40. The average price target represents an increase ...

Insulet announced amendments to its Annual Incentive Plan effective January 1, 2026, with revisions that impact terms regarding termination, retirement eligibility for prorated awards, compensation ...

Insulet stock (NASDAQ NDAQ: PODD) currently trades at $156 per share, about 29% lower than the level seen in early June 2022, just before the Fed started increasing rates, compared to 14% gains for ...